Evofem Biosciences Enters Material Definitive Agreement
Ticker: EVFM · Form: 8-K · Filed: Mar 26, 2025 · CIK: 1618835
Sentiment: neutral
Topics: material-agreement, corporate-news
Related Tickers: EVFM
TL;DR
Evofem (EVFM) signed a big deal, filing an 8-K today.
AI Summary
Evofem Biosciences, Inc. announced on March 20, 2025, that it entered into a material definitive agreement. The company, formerly known as Neothetics, Inc., is based in San Diego, California, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing indicates a significant new contract or partnership for Evofem Biosciences, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can carry significant risks depending on the nature of the agreement, which is not fully detailed in this initial filing.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- Neothetics, Inc. (company) — Former company name
- March 20, 2025 (date) — Date of earliest event reported
- San Diego, California (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Evofem Biosciences?
The filing states that Evofem Biosciences, Inc. entered into a material definitive agreement on March 20, 2025, but the specific details of the agreement are not provided in this initial 8-K filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 20, 2025.
What was Evofem Biosciences, Inc. formerly known as?
Evofem Biosciences, Inc. was formerly known as Neothetics, Inc.
Where are Evofem Biosciences, Inc.'s principal executive offices located?
Evofem Biosciences, Inc.'s principal executive offices are located at 7770 Regents Road, Suite 113-618, San Diego, California 92122.
What is Evofem Biosciences, Inc.'s Standard Industrial Classification code?
Evofem Biosciences, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 26, 2025 regarding Evofem Biosciences, Inc. (EVFM).